Table 3.
Clinical trials of bevacizumab in gliomas
| Study | Additional agents | Hisotology | Setting | Phase |
|---|---|---|---|---|
| Vredenburgh et al80 | Irinotecan | GBM,AA,AOA,AO | Recurrent | II |
| Vredenburgh et al81 | Irinotecan | GBM | Recurrent | II |
| Chen et al76 | Irinotecan | GBM,AA | Recurrent | II |
| Lai et al84 | Temezolomide | GBM | Newly diagnosed | II (safety report) |
Notes: The paper by Lai and colleagues84 reports the preliminary safety results on the first 10 patients of a larger phase II clinical trial.
Abbreviations: GBM, glioblastoma multiforme; AA, anaplastic astrocytoma; AOA, anaplastic oligoastrocytoma; AO, anaplastic oligodendroglioma.